{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:45:20Z","timestamp":1785249920699,"version":"3.55.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiologie"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00117-026-01564-z","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T10:43:38Z","timestamp":1770720218000},"page":"189-198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immuncheckpoint-Inhibitor-assoziierte Pneumonitiden","Immune checkpoint inhibitor-related pneumonitis"],"prefix":"10.1007","volume":"66","author":[{"given":"Anne Bettina","family":"Beeskow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Mura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Kifjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sanzharovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Prosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"1564_CR1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02072-2017","volume":"51","author":"A Costantini","year":"2018","unstructured":"Costantini\u00a0A et\u00a0al (2018) Immunotherapy: a new standard of care in thoracic malignancies?: A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly. Eur Respir J 51:1702072","journal-title":"Eur Respir J"},{"key":"1564_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41571-019-0317-y","volume":"17","author":"AC Chiang","year":"2020","unstructured":"Chiang\u00a0AC, Herbst\u00a0RS (2020) Frontline immunotherapy for NSCLC \u2014 the tale of the tail. Nat Rev Clin Oncol 17:73\u201374","journal-title":"Nat Rev Clin Oncol"},{"key":"1564_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pccm.2024.12.001","volume":"3","author":"Y Xu","year":"2025","unstructured":"Xu\u00a0Y et\u00a0al (2025) Clinical management of checkpoint inhibitor pneumonitis: Focus, challenges, and future directions. Chinese Medical Journal Pulmonary and Critical Care Medicine 3:29\u201340","journal-title":"Chinese Medical Journal Pulmonary and Critical Care Medicine"},{"key":"1564_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot\u00a0JM et\u00a0al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. European Journal of Cancer 54:139\u2013148","journal-title":"European Journal of Cancer"},{"key":"1564_CR5","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20200409","volume":"93","author":"TW Nobashi","year":"2020","unstructured":"Nobashi\u00a0TW et\u00a0al (2020) Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers. BJR 93:20200409","journal-title":"BJR"},{"key":"1564_CR6","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen\u00a0J et\u00a0al (2022) Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology 33:1217\u20131238","journal-title":"Annals of Oncology"},{"key":"1564_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer\u00a0JR et\u00a0al (2021) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J\u00a0Immunother Cancer 9:e002435","journal-title":"J Immunother Cancer"},{"key":"1564_CR8","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang\u00a0DY et\u00a0al (2018) Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol 4:1721\u20131721","journal-title":"JAMA Oncol"},{"key":"1564_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000840","volume":"8","author":"J Naidoo","year":"2020","unstructured":"Naidoo\u00a0J et\u00a0al (2020) Chronic immune checkpoint inhibitor pneumonitis. J\u00a0Immunother Cancer 8:e000840","journal-title":"J Immunother Cancer"},{"key":"1564_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14176133","volume":"14","author":"A Casal","year":"2025","unstructured":"Casal\u00a0A et\u00a0al (2025) Lung Toxicity from Immune Checkpoint Inhibitors: A Diagnostic Approach. JCM 14:6133","journal-title":"JCM"},{"key":"1564_CR11","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jtho.2018.11.016","volume":"14","author":"K Suresh","year":"2019","unstructured":"Suresh\u00a0K et\u00a0al (2019) Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy. Journal of Thoracic Oncology 14:494\u2013502","journal-title":"Journal of Thoracic Oncology"},{"key":"1564_CR12","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s42399-020-00259-3","volume":"2","author":"T Koyauchi","year":"2020","unstructured":"Koyauchi\u00a0T et\u00a0al (2020) Clinical Outcomes of Anti-programmed Death\u20111 Antibody\u2013Related Pneumonitis in Patients with Non-Small Cell Lung Cancer. SN Compr. Clin. Med 2:570\u2013578","journal-title":"SN Compr. Clin. Med"},{"key":"1564_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.830631","volume":"13","author":"J Yin","year":"2022","unstructured":"Yin\u00a0J, Wu\u00a0Y, Yang\u00a0X, Gan\u00a0L, Xue\u00a0J (2022) Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1\/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism. Front. Immunol 13:830631","journal-title":"Front. Immunol"},{"key":"1564_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2453","volume":"2","author":"M Nishino","year":"2016","unstructured":"Nishino\u00a0M, Giobbie-Hurder\u00a0A, Hatabu\u00a0H, Ramaiya\u00a0NH, Hodi\u00a0FS (2016) Incidence of Programmed Cell Death 1 Inhibitor\u2013Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. JAMA Oncol 2:1607","journal-title":"JAMA Oncol"},{"key":"1564_CR15","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cllc.2023.08.014","volume":"24","author":"M Petranovic","year":"2023","unstructured":"Petranovic\u00a0M et\u00a0al (2023) Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis Risk in Patients Receiving Immune Checkpoint Inhibitors for Non\u2013Small-Cell Lung Cancer. Clinical Lung Cancer 24:682\u2013688.e5","journal-title":"Clinical Lung Cancer"},{"key":"1564_CR16","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cllc.2023.08.014","volume":"24","author":"M Petranovic","year":"2023","unstructured":"Petranovic\u00a0M et\u00a0al (2023) Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis Risk in Patients Receiving Immune Checkpoint Inhibitors for Non\u2013Small-Cell Lung Cancer. Clinical Lung Cancer 24:682\u2013688","journal-title":"Clinical Lung Cancer"},{"key":"1564_CR17","doi-asserted-by":"publisher","DOI":"10.36416\/1806-3756\/e20240110","author":"G Das Posses Bridi","year":"2024","unstructured":"Das Posses Bridi\u00a0G, Kaiser Ururahy Nunes Fonseca\u00a0E, Adib Kairalla\u00a0R, Franco Amaral\u00a0A, Guedes Baldi\u00a0B (2024) Drug-induced lung disease: a narrative review. J\u00a0Bras Pneumole20240110. https:\/\/doi.org\/10.36416\/1806-3756\/e20240110","journal-title":"J Bras Pneumol"},{"key":"1564_CR18","doi-asserted-by":"crossref","unstructured":"Rizvi, N. A. et\u00a0al. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non\u2013Small Cell Lung Cancer: The MYSTIC Phase\u00a03 Randomized Clinical Trial. JAMA Oncol 6, 661 (2020).","DOI":"10.1001\/jamaoncol.2020.0237"},{"key":"1564_CR19","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1002\/cncr.33083","volume":"126","author":"GA Durm","year":"2020","unstructured":"Durm\u00a0GA et\u00a0al (2020) A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non\u2013small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. Cancer 126:4353\u20134361","journal-title":"Cancer"},{"key":"1564_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.lungcan.2019.05.001","volume":"133","author":"S Peters","year":"2019","unstructured":"Peters\u00a0S et\u00a0al (2019) Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer\u2014The ETOP NICOLAS trial. Lung Cancer 133:83\u201387","journal-title":"Lung Cancer"},{"key":"1564_CR21","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2024.12670","volume":"28","author":"S Lavalle","year":"2024","unstructured":"Lavalle\u00a0S et\u00a0al (2024) Immune checkpoint inhibitor therapy-related pneumonitis: How, when and why to diagnose and manage (Review). Exp Ther Med 28:381","journal-title":"Exp Ther Med"},{"key":"1564_CR22","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0). (2025)."},{"key":"1564_CR23","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1148\/radiol.2021203427","volume":"298","author":"T Johkoh","year":"2021","unstructured":"Johkoh\u00a0T et\u00a0al (2021) Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. Radiology 298:550\u2013566","journal-title":"Radiology"},{"key":"1564_CR24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.hemonc.2021.09.005","volume":"16","author":"H Banavasi","year":"2023","unstructured":"Banavasi\u00a0H et\u00a0al (2023) Immune Checkpoint Inhibitor-induced Pneumonitis: Incidence, Clinical Characteristics, and Outcomes. Hematology\/Oncology and Stem Cell Therapy 16:144\u2013150","journal-title":"Hematology\/Oncology and Stem Cell Therapy"},{"key":"1564_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14176133","volume":"14","author":"A Casal","year":"2025","unstructured":"Casal\u00a0A et\u00a0al (2025) Lung Toxicity from Immune Checkpoint Inhibitors: A Diagnostic Approach. JCM 14:6133","journal-title":"JCM"},{"key":"1564_CR26","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0073-2018","volume":"27","author":"SLF Walsh","year":"2018","unstructured":"Walsh\u00a0SLF et\u00a0al (2018) Role of imaging in progressive-fibrosing interstitial lung diseases. Eur Respir Rev 27:180073","journal-title":"Eur Respir Rev"},{"key":"1564_CR27","doi-asserted-by":"publisher","DOI":"10.1148\/rg.230165","volume":"44","author":"KJ Chae","year":"2024","unstructured":"Chae\u00a0KJ et\u00a0al (2024) Central Role of CT in Management of Pulmonary Fibrosis. RadioGraphics 44:e230165","journal-title":"RadioGraphics"},{"key":"1564_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-025-11715-w","author":"J Choi","year":"2025","unstructured":"Choi\u00a0J et\u00a0al (2025) Effect of contrast enhancement on diagnosis of interstitial lung abnormality in automatic quantitative CT measurement. Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-025-11715-w","journal-title":"Eur Radiol"},{"key":"1564_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.chstcc.2024.100126","volume":"3","author":"K Montemayor","year":"2025","unstructured":"Montemayor\u00a0K, Ghanbar\u00a0MI, Koch\u00a0AL, Suresh\u00a0K, Stephens\u00a0RS (2025) Managing Immune Checkpoint Inhibitor Pneumonitis in the ICU. CHEST Critical Care 3:100126","journal-title":"CHEST Critical Care"},{"key":"1564_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer\u00a0JR, Society for Immunotherapy of Cancer (SITC) et\u00a0al (2021) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J\u00a0Immunother Cancer 9:e002435","journal-title":"J Immunother Cancer"},{"key":"1564_CR31","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","volume":"35","author":"J Naidoo","year":"2017","unstructured":"Naidoo\u00a0J et\u00a0al (2017) Pneumonitis in Patients Treated With Anti\u2013Programmed Death-1\/Programmed Death Ligand 1 Therapy. JCO 35:709\u2013717","journal-title":"JCO"},{"key":"1564_CR32","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.2214\/AJR.16.17315","volume":"208","author":"A Bernheim","year":"2017","unstructured":"Bernheim\u00a0A, McLoud\u00a0T (2017) A Review of Clinical and Imaging Findings in Eosinophilic Lung Diseases. American Journal of Roentgenology 208:1002\u20131010","journal-title":"American Journal of Roentgenology"},{"key":"1564_CR33","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00165-2019","volume":"6","author":"C Pozzessere","year":"2020","unstructured":"Pozzessere\u00a0C et\u00a0al (2020) Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a\u00a0retrospective study. ERJ Open Res 6:00165\u201302019","journal-title":"ERJ Open Res"},{"key":"1564_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107640","volume":"227","author":"H Smith","year":"2024","unstructured":"Smith\u00a0H et\u00a0al (2024) Sarcoid-like reactions to immune checkpoint inhibitors: Incidence, treatment course, and impact on cancer progression and survival. Respiratory Medicine 227:107640","journal-title":"Respiratory Medicine"},{"key":"1564_CR35","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jtho.2018.04.031","volume":"13","author":"I Gkiozos","year":"2018","unstructured":"Gkiozos\u00a0I et\u00a0al (2018) Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors. Journal of Thoracic Oncology 13:1076\u20131082","journal-title":"Journal of Thoracic Oncology"},{"key":"1564_CR36","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1097\/PAS.0000000000001298","volume":"43","author":"BT Larsen","year":"2019","unstructured":"Larsen\u00a0BT et\u00a0al (2019) Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-related Pneumonitis. American Journal of Surgical Pathology 43:1331\u20131340","journal-title":"American Journal of Surgical Pathology"},{"key":"1564_CR37","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1183\/09031936.06.00013505","volume":"28","author":"JF Cordier","year":"2006","unstructured":"Cordier\u00a0JF (2006) Cryptogenic organising pneumonia. Eur Respir J 28:422\u2013446","journal-title":"Eur Respir J"},{"key":"1564_CR38","doi-asserted-by":"publisher","DOI":"10.1148\/rg.230165","volume":"44","author":"KJ Chae","year":"2024","unstructured":"Chae\u00a0KJ et\u00a0al (2024) Central Role of CT in Management of Pulmonary Fibrosis. RadioGraphics 44:e230165","journal-title":"RadioGraphics"},{"key":"1564_CR39","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00158-2025","author":"CJ Ryerson","year":"2025","unstructured":"Ryerson\u00a0CJ et\u00a0al (2025) Update of the International Multidisciplinary Classification of the Interstitial Pneumonias: An ERS\/ATS Statement. Eur Respir J2500158. https:\/\/doi.org\/10.1183\/13993003.00158-2025","journal-title":"Eur Respir J"},{"key":"1564_CR40","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s13244-014-0335-3","volume":"5","author":"S Palmucci","year":"2014","unstructured":"Palmucci\u00a0S et\u00a0al (2014) Clinical and radiological features of idiopathic interstitial pneumonias (IIPs): a pictorial review. Insights Imaging 5:347\u2013364","journal-title":"Insights Imaging"},{"key":"1564_CR41","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0006-2024","volume":"20","author":"C Lederer","year":"2024","unstructured":"Lederer\u00a0C et\u00a0al (2024) Imaging in the diagnosis and management of fibrosing interstitial lung diseases. Breathe 20:240006","journal-title":"Breathe"},{"key":"1564_CR42","unstructured":"Raphaely, R. A. et\u00a0al. Radiographic Features Associated With Histopathologic Bronchiolocentric Interstitial Pneumonia."},{"key":"1564_CR43","unstructured":"Isono, T. et\u00a0al. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors."},{"key":"1564_CR44","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/his.14704","volume":"81","author":"S Imran","year":"2022","unstructured":"Imran\u00a0S et\u00a0al (2022) Immune check-point inhibitor-related pneumonitis: acute lung injury with rapid progression and organising pneumonia with less severe clinical disease. Histopathology 81:724\u2013731","journal-title":"Histopathology"},{"key":"1564_CR45","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/his.14704","volume":"81","author":"S Imran","year":"2022","unstructured":"Imran\u00a0S et\u00a0al (2022) Immune check-point inhibitor-related pneumonitis: acute lung injury with rapid progression and organising pneumonia with less severe clinical disease. Histopathology 81:724\u2013731","journal-title":"Histopathology"},{"key":"1564_CR46","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejca.2020.09.025","volume":"141","author":"JD Karam","year":"2020","unstructured":"Karam\u00a0JD et\u00a0al (2020) Infectious complications in patients treated with immune checkpoint inhibitors. European Journal of Cancer 141:137\u2013142","journal-title":"European Journal of Cancer"},{"key":"1564_CR47","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.rmed.2018.11.021","volume":"146","author":"K Fujita","year":"2019","unstructured":"Fujita\u00a0K et\u00a0al (2019) Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy. Respiratory Medicine 146:66\u201370","journal-title":"Respiratory Medicine"},{"key":"1564_CR48","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/1759-7714.13240","volume":"11","author":"H Wang","year":"2020","unstructured":"Wang\u00a0H et\u00a0al (2020) Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. Thoracic Cancer 11:191\u2013197","journal-title":"Thoracic Cancer"},{"key":"1564_CR49","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejrad.2019.04.025","volume":"116","author":"L Cereser","year":"2019","unstructured":"Cereser\u00a0L et\u00a0al (2019) Pneumocystis jirovecii pneumonia at chest High-resolution Computed Tomography (HRCT) in non-HIV immunocompromised patients: Spectrum of findings and mimickers. European Journal of Radiology 116:116\u2013127","journal-title":"European Journal of Radiology"},{"key":"1564_CR50","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1148\/rg.2018170048","volume":"38","author":"HJ Koo","year":"2018","unstructured":"Koo\u00a0HJ et\u00a0al (2018) Radiographic and CT Features of Viral Pneumonia. RadioGraphics 38:719\u2013739","journal-title":"RadioGraphics"},{"key":"1564_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-19","volume":"2","author":"C Kyi","year":"2014","unstructured":"Kyi\u00a0C, Hellmann\u00a0MD, Wolchok\u00a0JD, Chapman\u00a0PB, Postow\u00a0MA (2014) Opportunistic infections in patients treated with immunotherapy for cancer. J\u00a0Immunother Cancer 2:19","journal-title":"J Immunother Cancer"},{"key":"1564_CR52","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.rmed.2018.11.021","volume":"146","author":"K Fujita","year":"2019","unstructured":"Fujita\u00a0K et\u00a0al (2019) Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy. Respiratory Medicine 146:66\u201370","journal-title":"Respiratory Medicine"},{"key":"1564_CR53","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1259\/bjr\/39696316","volume":"80","author":"MN Vogel","year":"2007","unstructured":"Vogel\u00a0MN et\u00a0al (2007) Differences and similarities of cytomegalovirus and pneumocystis pneumonia in HIV-negative immunocompromised patients \u2013 thin section CT morphology in the early phase of the disease. BJR 80:516\u2013523","journal-title":"BJR"},{"key":"1564_CR54","volume":"2","author":"TMH De Jaegere","year":"2020","unstructured":"De Jaegere\u00a0TMH, Krdzalic\u00a0J, Fasen\u00a0BACM, Kwee\u00a0RM, COVID-19 CT Investigators South-East Netherlands (CISEN) study group (2020) Radiological Society of North America Chest CT Classification System for Reporting COVID-19 Pneumonia: Interobserver Variability and Correlation with Reverse-Transcription Polymerase Chain Reaction. Radiology: Cardiothoracic Imaging 2:e200213","journal-title":"Radiology: Cardiothoracic Imaging"},{"key":"1564_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.577696","volume":"10","author":"DW Dumoulin","year":"2020","unstructured":"Dumoulin\u00a0DW, Gietema\u00a0HA, Paats\u00a0MS, Hendriks\u00a0LEL, Cornelissen\u00a0R (2020) Differentiation of COVID-19 Pneumonitis and ICI Induced Pneumonitis. Front Oncol 10:577696","journal-title":"Front Oncol"},{"key":"1564_CR56","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1055\/a-1174-8378","volume":"192","author":"J Vogel-Claussen","year":"2020","unstructured":"Vogel-Claussen\u00a0J et\u00a0al (2020) Recommendations of the Thoracic Imaging Section of the German Radiological Society for clinical application of chest imaging and structured CT reporting in the COVID-19 pandemic. Rofo 192:633\u2013640","journal-title":"Rofo"},{"key":"1564_CR57","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S0140-6736(24)02319-5","volume":"405","author":"II Verginadis","year":"2025","unstructured":"Verginadis\u00a0II et\u00a0al (2025) Radiotherapy toxicities: mechanisms, management, and future directions. The Lancet 405:338\u2013352","journal-title":"The Lancet"},{"key":"1564_CR58","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1148\/rg.2019180061","volume":"39","author":"MF Benveniste","year":"2019","unstructured":"Benveniste\u00a0MF et\u00a0al (2019) Recognizing Radiation Therapy\u2013related Complications in the Chest. RadioGraphics 39:344\u2013366","journal-title":"RadioGraphics"},{"key":"1564_CR59","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.crad.2021.04.013","volume":"77","author":"CD Strange","year":"2022","unstructured":"Strange\u00a0CD et\u00a0al (2022) Imaging of the post-radiation chest in lung cancer. Clinical Radiology 77:19\u201330","journal-title":"Clinical Radiology"},{"key":"1564_CR60","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1148\/rg.244035160","volume":"24","author":"YW Choi","year":"2004","unstructured":"Choi\u00a0YW et\u00a0al (2004) Effects of Radiation Therapy on the Lung: Radiologic Appearances and Differential Diagnosis. RadioGraphics 24:985\u2013997","journal-title":"RadioGraphics"},{"key":"1564_CR61","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood\u00a0SS et\u00a0al (2018) Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. Journal of the American College of Cardiology 71:1755\u20131764","journal-title":"Journal of the American College of Cardiology"},{"key":"1564_CR62","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejim.2019.12.034","volume":"72","author":"C Sorino","year":"2020","unstructured":"Sorino\u00a0C, Negri\u00a0S, Spanevello\u00a0A, Feller-Kopman\u00a0D (2020) The pleura and the endocrine system. European Journal of Internal Medicine 72:34\u201337","journal-title":"European Journal of Internal Medicine"},{"key":"1564_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00604","volume":"11","author":"ME Farrugia","year":"2020","unstructured":"Farrugia\u00a0ME, Goodfellow\u00a0JAA (2020) A Practical Approach to Managing Patients With Myasthenia Gravis\u2014Opinions and a Review of the Literature. Front. Neurol 11:604","journal-title":"Front. Neurol"},{"key":"1564_CR64","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s42399-020-00259-3","volume":"2","author":"T Koyauchi","year":"2020","unstructured":"Koyauchi\u00a0T, Inui\u00a0N, Karayama\u00a0M et\u00a0al (2020) Clinical_Outcomes_of_Anti-programmed_Death-1_Antib. SN Comprehensive Clinical Medicine 2:570\u2013578","journal-title":"SN Comprehensive Clinical Medicine"}],"container-title":["Die Radiologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-026-01564-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00117-026-01564-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-026-01564-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T13:02:46Z","timestamp":1772110966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00117-026-01564-z"}},"subtitle":["Strategien zur differenzialdiagnostischen Einordnung","Differential diagnosis strategies"],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1564"],"URL":"https:\/\/doi.org\/10.1007\/s00117-026-01564-z","relation":{},"ISSN":["2731-7048","2731-7056"],"issn-type":[{"value":"2731-7048","type":"print"},{"value":"2731-7056","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"16 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.B.\u00a0Beeskow, R.\u00a0Mura, D.\u00a0Kifjak, M.\u00a0Sanzharovskaya und H.\u00a0Prosch geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}